A composition comprising isolated vascular-associated naturally pluripotent stem cells (vaPS), is disclosed, as well as method of treating defects using such composition, wherein said vaPS are capable of differentiating into somatic cells of all three germ layers under the guidance of the respective microenvironment.

A composition comprising isolated vascular-associated naturally pluripotent stem cells (vaPS), is disclosed, as well as method of treating defects using such composition, wherein said vaPS are capable of differentiating into somatic cells of all three germ layers under the guidance of the respective microenvironment.

The present invention relates to the use of derivatives between hyaluronic acid, heterocyclic compounds and naturally occurring amino acids in single, oligomeric or polymeric form for the treatment of skeletal diseases, in particular in the regeneration of bone and cartilage tissues.

The present invention relates to the use of derivatives between hyaluronic acid, heterocyclic compounds and naturally occurring amino acids in single, oligomeric or polymeric form for the treatment of skeletal diseases, in particular in the regeneration of bone and cartilage tissues.

The present invention relates to compounds of formula (I), wherein R.sup.1 to R.sup.3 and n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

##STR00001##

The embodiments of the present disclosure provide a manufacturing method of mitochondria-rich plasma. The mitochondria-rich plasma can increase the cell viability of damaged cells, decrease the cellular senescence level, repair the oxidative damage of cells, and relieve the inflammation of hair follicles so as to achieve the purpose of promoting hair regrowth.

The present invention relates to compounds of formula (I), wherein R.sup.1 to R.sup.3 and n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

##STR00001##

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

This discloses that compounds of Formula 1 may be used as antifibrotics because they inhibit type 1 collagen production. In particular, this discloses a pharmaceutical composition containing one or more compounds of Formula 1 and methods of using compounds of Formula 1 in fibrosis treatment and inhibiting type 1 collagen synthesis.